Thus, these findings suggested that high expression of TFAP2A and ESR2 may influence targeted therapy and that PHTPP may sensitise NSCLC to high TFAP2A expression (Fig. 7). The gene discussed is ESR2; the disease is non-small cell lung carcinoma.